Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lannett Confident Of $1bn In Sales By 2025

Lantus And Advair Among Key Projects

Aug 27 2020

• By Dean Rudge

US-Money-and-Pills_V2_1200x675 — Complex dosage forms via partnerships are driving Lannett towards growth in the future • Source: Shutterstock

Related Content

Lannett Makes Deal For Respirent’s Flovent Diskus Rival

Aug 18 2020

Amneal Approval Leads Lannett To Job Losses

Jul 13 2020

Related Companies

Lannett Company, Inc.

Additional Topics

United States Strategy Sales & Earnings Biosimilars Generic Drugs BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.